Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBDV in Prader-Willi Syndrome
NCT03848481Phase 2Terminated
- Start
- Nov 2020
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidivarin in Prader-Willi syndrome (PWS). Started Nov 2020; status: terminated.
02
Drugs
cannabidivarin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT03848481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848481.